Profound Medical Corp Stock News

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROFOUND MEDICAL CORP. (PR...

PHILADELPHIA, PA / ACCESS Newswire / March 13, 2025 / Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Profound Medical Corp. ("Profound Medical," "Profound," or the "Company") (NASDAQ:PROF).

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PROFOUND MEDICAL CORP. (PROF), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSU...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROFOUND MEDICAL CORP. (PROF), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER ...

Profound Medical Corporation (NASDAQ:PROF ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Stephen Kilmer – IR Rashed Dewan - CFO Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat – CEO Conference Call Participants John Baugh - Stifel Michael Freeman - Raymond James Operator Thank you for standing by and welcome to the Profound Medical ...

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.

– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16 th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or th...